Loading
Life sciences · Journal article
Future Medicinal Chemistry · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
AIMS: ) was designed, synthesized, and evaluated as potential aromatase inhibitors with anticancer activity. MATERIALS AND METHODS: ADMET profiling were performed for the selected compounds. RESULTS: values (2.40-2.64 µM), surpassing cisplatin, while maintaining favorable selectivity profiles. CONCLUSIONS: as a promising lead for further development as a non-steroidal aromatase inhibitor for breast cancer therapy.